Skip Navigation LinksHome > Studies > ADNI 2 study  

ADNI 2 Study


The Alzheimer’s Disease Neuroimaging Initiative (ADNI), a landmark study that began in 2004, is a public-private research partnership tasked with identifying biomarkers to detect Alzheimer’s disease (AD). The study has gathered and analyzed thousands of brain scans, genetic profiles and biomarkers in blood and cerebrospinal fluid (CSF). The study was designed to enable researchers to follow AD as it progresses in an individual, from various points in the disease process.

In 2009, ADNI made a significant step forward in providing validation for a test that helps diagnose the beginning stages of AD sooner and more accurately by measuring levels of two biomarkers—tau and beta-amyloid proteins—in cerebrospinal fluid. Biomarkers in cerebrospinal fluid are revealing other changes that could identify which patients with MCI may develop Alzheimer’s.

The ADNI study includes scientists at 55 research centers in U.S. and Canada. Currently the study involves over 800 study participants from those without memory problems to mild cognitive impairment to AD. The study results are expected to provide researchers with a better understanding of AD progression in its earliest stages.

In 2010, funded by the federal stimulus package, the ADNI study moved into the “ADNI GO” phase. The ADNI GO research effort is the first of its kind to focus on participants who exhibit the earliest signs of memory loss in mild cognitive impairment – both thought to be precursors to AD. While the ADNI GO project work continues, the overall ADNI effort is rapidly moving into a third phase – known as “ADNI 2”.


ADNI 2 will build upon the successes of earlier ADNI phases to identify the earliest signs of Alzheimer’s disease. Researchers are eager to determine when damage to the brain begins. Scientists suspect that identifiable changes to the brain take place well before AD symptoms appear. The ADNI2 phase of the study includes a large number of new volunteers in the earliest stages of cognitive impairment.

Researchers are seeking new volunteers to join those already participating in the study as it enters the ADNI2 phase. The study participants will be followed to define any changes in brain structure and function as people transition from normal cognitive aging to mild cognitive impairment (MCI) to AD. Like the previous phases of the study researchers will use imaging techniques and biomarker measures in blood and CSF specially developed to track changes in the living brain.

ADNI Technologies and Biomarkers

Some of the leading-edge technologies used in the ADNI studies are brain-imaging techniques, such as positron emission tomography (PET), including FDG-PET (which measures glucose metabolism in the brain); PET using a radioactive compound (Florbetapir F 18) that measures brain amyloid accumulation; that measures brain beta-amyloid; and structural MRI. Brain scans are showing scientists how the brain’s structure and function change as AD starts and progresses. Moreover, biomarkers in CSF are revealing other changes that could identify which patients with MCI will develop Alzheimer’s. ADNI 2 researchers are committed to identifying who is at risk for Alzheimer’s and to developing measurements to accurately track the progression of the disease in an individual. Moreover, ADNI 2 researchers hope to develop tests to measure the effectiveness of potential AD treatment interventions.

Volunteering for ADNI 2

ADNI 2 is actively enrolling through August 2013 and the study will run through 2017.

Researchers are looking for 550 volunteers between the ages of 55 and 90:

  • 150 with no apparent memory problems
  • 100 with a significant memory concern
  • 100 with early mild cognitive impairment (eMCI)
  • 150 with late mild cognitive impairment (lMCI)
  • 150 with mild AD

All ADNI 2 volunteers should be:

  • In good general health
  • Fluent in English or Spanish
  • Willing and able to undergo the test procedures)
  • Accompanied by a study partner – a friend or relative who can go with the volunteer to all clinic visits and has at least 10 hours of contact per week with the volunteer.

U.S. Clinical Study Research Sites Participating in the ADNI 2 Study:

StateCityZip CodeLocationContact
ALBirmingham  University of Alabama, Birmingham

Denise Ledlow
AZSun City  Banner Sun Health Research Institute

Sherye Sirrel
CAIrvine  University of California, Irvine

Beatriz Yanez
CALa Jolla  University of California, San Diego

Helen Vanderswag
CALos Angeles  University of Southern California

Mauricio Becerra
CALos Angeles  University of California, Los Angeles

Michelle Mather
CAOrange  University of California, Irvine - Neuropsychiatric Center

Ioana Popica
CAPalo Alto  Stanford University

Michael Nolasco
CASan Francisco  University of California, San Francisco

Samuel Stark
CTNew Haven  Yale University School of Medicine

Melinda Becker
DCWashington  Howard University

Saba Wolday
DCWashington20057 Georgetown University

Kelly Behan
FLJacksonville  Mayo Clinic, Jacksonville

Kim-Poki Walker Moore
FLMiami Beach  Wien Center for Clinical Research

Maria Greig-Custo
(305)674-2121 ext 54480
FLPalm Beach  Premiere Research Institute

Teresa Villena
(561)845-0500 ext 124
FLTampa33613 University of South Florida - Health Byrd Alzheimer Institute
4001 E. Fletcher Avenue

Jill Smith
GAAtlanta  Emory University

Rebecca Byram
GAAtlanta  Emory University

Cecelia Manzanares
IAIowa City  University of Iowa

Karen Smith
ILChicago  Northwestern University

Kristine Lipowski
ILChicago  Rush University Medical Center

Patricia Samuels
(312) 942-3033
INIndianapolis  Indiana University

Scott Herring
KSKansas City  University of Kansas

Timothy Welch
(913) 945-6792
KYLexington  University of Kentucky

Barbara Martin
MABoston  Boston University

Meenakshi Chivukula
(617) 638-8390
MABoston  Brigham and Women's Hospital

Lidya Poni
MDBaltimore  Johns Hopkins University

Daniel D'Agostino II
(410) 502-6161
MIAnn Arbor  University of Michigan, Ann Arbor

Joanne Lord
MNRochester  Mayo Clinic, Rochester

Kris Johnson
(507) 284-6407
MOSt. Louis  Washington University, St. Louis

Maria Carroll
NCDurham  Duke University Medical Center

Cammie Hellegers
(919) 681-3986
NCWinston-Salem  Wake Forest University Health Sciences

Leslie Gordineer
NHLebanon  Dartmouth Medical Center

Mary Hynes
(603) 650-7552
NVLas Vegas  Cleveland Clinic Lou Ruvo Center for Brain Health

Triny Cooper
(702) 483-6013
NYAlbany  Albany Medical College

Paula Malone
(518) 264-1130
NYAmherst  Dent Neurologic Institute

Michelle Rainka
NYNew York  Mount Sinai School of Medicine

Kelly Pun
NYNew York  New York University Medical Center

Brittany Cerbone
NYNew York  Columbia University

Martina Azar
(212) 342-0522
NYNew York  Weill Cornell Memory Disorders Program

Gabriella Arth
(212) 746-6580
NYOrangeburg10962 Nathan Kline Institute for Psychiatric Research
140 Old Orangeburg Road, Bldg. 35

Vita Pomara
NYRochester  University of Rochester Medical Center

Bonnie Goldstein
NYRochester  University of Rochester Medical Center

Nancy Kowalski
OHCleveland  Case Western Reserve University

Parianne Fatica
OHColumbus  Ohio State University

Jennifer Icenhour
(614) 293-6882
ORPortland  Oregon Health & Science University

Betty Lind
PAPhiladelphia  University of Pennsylvania

Jessica Nunez-Lopez
PAPittsburgh  University of Pittsburgh

MaryAnn Oakley
RIProvidence  Rhode Island Hospital

Juliette Belliard
RIProvidence  Butler Hospital Memory and Aging Program

Rosalind Mandelbaum
SCCharleston  Roper St. Francis Hospital

Arthur Williams
(843)724-2302 ext 6375
SCCharleston  Roper St. Francis Hospital

Stephen Bagg
SCNorth Charleston  Medical University of South Carolina

Arthur Williams
(843)724-2302 ext 6375
TXDallas  University of Texas, Southwestern MC at Dallas

Jacqueline Rabb
(214) 648-9358
TXHouston  Baylor College of Medicine

Munir Chowdhury
(713) 798-4734
WIMadison  University of Wisconsin

Sandra Harding

Canadian Clinical Study Research Sites Participating in the ADNI 2 Study:

StateCityZip CodeLocationContact
British ColumbiaVancouverV6T 2B5 University of British Columbia, Clinic for AD & Related

Benita Mudge
OntarioLondonN6C 5J1 Parkwood Hospital

Charlene Bartha
(519)685-4292 x42286
OntarioLondonN6A 4V2 St. Joseph's Health Center - Cognitive Neurology

Charlene Bartha
(519)685-4292 x42286
OntarioLondonN6C 5J1 Parkwood Hospital

Patricia Sargeant
+519)685-4292 Ext. 42896
OntarioLondonN6A 4V2 St. Joseph's Health Center - Cognitive Neurology

Patricia Sargeant
+519)685-4292 Ext. 42896
OntarioTorontoM4N 3M5 Sunnybrook Health Sciences Centre

Joanne Lawrence
(416) 480-6108
QuebecMontrealH3T 1E2 McGill University / Jewish General Hospital Memory Clinic

Chris Hosein
(514)340-8222, ext 3621

For more information on this study go to: